Erythropoietin/EPO 蛋白, Human (CHO)

Erythropoietin/EPO is a renal cytokine that activates Akt and NF-κB signaling pathways by binding to erythroid progenitor cells EPOR. Erythropoietin/EPO regulates erythroid proliferation and differentiation and inhibits apoptosis. Erythropoietin/EPO also has angiogenic ability comparable to VEGF and can stimulate endothelial cell capillary sprouting. Erythropoietin/EPO can be used in the study of ischemic heart diseases such as anemia in end-stage renal disease. Erythropoietin/EPO Protein, Human (CHO) is a recombinant Erythropoietin/EPO protein expressed in CHO cells with tag-free.

促红细胞生成素 Erythropoietin/EPO，是一种主要由肾脏产生的糖蛋白，属于细胞因子超家族。Erythropoietin/EPO 通过与红细胞祖细胞 (CFU-E 和 BFU-E) 上的促红细胞生成素受体 (EPOR) 结合，激活 Akt 和 NF-κB 等信号通路，调节红细胞增殖和分化，促进细胞存活并抑制凋亡。Erythropoietin/EPO 还具有与 VEGF 相当的促血管生成潜力，可刺激内皮细胞毛细血管萌发，并通过减轻凋亡和炎症保护组织免受缺血-再灌注损伤。临床上，重组人 Erythropoietin/EPO (rh-EPO) 可用于抑制终末期肾病贫血的研究，并在缺血性心脏病、神经系统损伤和治疗性血管生成中具有潜在应用价值。

Erythropoietin/EPO 蛋白 (人源；2.5 U/mL；21 d) 可刺激成人人类心肌组织来源的内皮细胞的血管生成实，增加毛细血管生长，与 VEGF₁₆₅ 的血管生成潜力相当^[1]。
Erythropoietin/EPO 蛋白 (人源；0.24 U/mL；4 d) 可诱导小鼠胎儿肝细胞的血红蛋白合成红细胞集落，且该过程与粒细胞集落的形成独立调控^[2]。

Erythropoietin/EPO Protein 蛋白 (人源；1、5、25 μg/kg；静脉注射；2 次) 对大鼠给药后，血浆浓度呈双指数下降，清除率随剂量增加而降低，血细胞比容显著升高，EC₅₀ 为 0.383 ng/mL^[4]。Erythropoietin/EPO Protein 蛋白 (人源；1、5、25 μg/kg；皮下注射；2 次) 对大鼠给药后，C_max/D 随剂量增加而升高，血细胞比容显著升高^[4]。
Erythropoietin/EPO Protein 蛋白 (人源 rh-EPO；0.2-5 μg/kg；静脉注射；单剂量) 处理大鼠后，其全身清除率随剂量增加而降低，在高剂量时趋于稳定。靶组织 (例如骨髓和脾脏) 对 ¹²⁵I-rh-EPO 的吸收清除率呈现明显的饱和状态。而单次皮下注射 rh-EPO (1 μg/kg) 导致骨髓和脾脏对 ¹²⁵I-rh-EPO 的组织摄取清除率降低 (下调)^[5]。

The ED₅₀ is ≤2.299 ng/mL as measured in a cell proliferation assay using TF-1 human erythroleukemic cells, corresponding to a specific activity of ≥4.350× 10⁵ units/mg.

• 
  Measured in a cell proliferation assay using TF-1 human erythroleukemic cells. The ED₅₀ for this effect is 1.136 ng/mL, corresponding to a specific activity is 8.803×10⁵ U/mg

Human

CHO

Tag Free

P01588 (A28-R193)

2056  [NCBI]

Full Length of Mature Protein

APPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYAWKRMEVGQQAVEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLRSLTTLLRALGAQKEAISPPDAASAAPLRTITADTFRKLFRVYSNFLRGKLKLYTGEACRTGDR

Approximately 26-38 kDa due to glycosylation.

• 
  Greater than 95% as determined by reducing SDS-PAGE.

无菌粉末

Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4.

<0.2 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.

• [1]. Calvillo L, et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4802-6.  [Content Brief]

  [2]. Jaquet K, et al. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res. 2002 Sep;64(2):326-33.  [Content Brief]

  [3]. Stephenson JR, et al. Induction of colonies of hemoglobin-synthesizing cells by erythropoietin in vitro. Proc Natl Acad Sci U S A. 1971 Jul;68(7):1542-6.  [Content Brief]

  [4]. Kato M, et al. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in rats. Arzneimittelforschung. 2001 Jan;51(1):91-5.  [Content Brief]

  [5]. Kato M, et al. Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats. J Pharmacol Exp Ther. 1997 Nov;283(2):520-7.  [Content Brief]